k141_37549_24	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	27.2	224	288	255	1.62e-24	98.2
k141_37549_24	SARG|gb|AAK76137.1|ARO:3000024|patA	30.6	235	288	564	6.88e-21	91.3
k141_37549_24	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	30.8	240	288	579	1.28e-20	90.5
k141_37549_24	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	30.4	240	288	579	1.06e-19	87.8
k141_37549_24	SARG|gb|WP_104671188.1|ARO:3003948|efrA	30.9	233	288	575	6.38e-19	85.5
k141_37549_24	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	27.9	240	288	578	1.28e-17	81.6
k141_37549_24	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.4	238	288	664	1.84e-17	81.3
k141_37549_24	SARG|gb|AAK76136.1|ARO:3000025|patB	28.5	235	288	588	2.76e-15	74.7
k141_37549_24	SARG|gb|APB03219.1|ARO:3003986|TaeA	26.6	188	288	648	2.90e-08	53.5
k141_37549_25	SARG|gi|671541568|ref|WP_031525212.1|	36.6	216	285	648	9.20e-34	128
k141_37549_25	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	37.2	199	285	293	7.99e-29	110
k141_37549_25	SARG|gi|507050365|ref|WP_016121371.1|	29.9	221	285	309	4.02e-25	100
k141_37549_25	SARG|gi|445996708|ref|WP_000074563.1|	30.3	221	285	309	4.02e-25	100
k141_37549_25	SARG|gi|447057510|ref|WP_001134766.1|	29.9	221	285	309	5.57e-25	100
k141_37549_25	SARG|gi|488120365|ref|WP_002191762.1|	29.4	221	285	309	7.72e-25	100
k141_37549_25	SARG|gi|488068784|ref|WP_002140181.1|	30.3	221	285	309	1.07e-24	99.8
k141_37549_25	SARG|gi|488067981|ref|WP_002139378.1|	29.9	221	285	309	1.48e-24	99.4
k141_37549_25	SARG|gi|507055561|ref|WP_016126482.1|	30.3	221	285	309	1.48e-24	99.4
k141_37549_25	SARG|gi|488053456|ref|WP_002124853.1|	30.3	221	285	309	1.48e-24	99.4
k141_37549_26	SARG|gb|APB03216.1|ARO:3003982|LlmA	56.1	285	285	287	6.65e-114	328
k141_37549_39	NCBI|WP_011906899.1|1|1|estDL136|estDL136||2|CHLORAMPHENICOL/FLORFENICOL|PHENICOL|phenicol_hydrolase|AMR|phenicol	32.7	220	300	308	6.26e-21	89.7
k141_37549_39	megares|MEG_2865|Drugs|Phenicol|Chloramphenicol_hydrolase|ESTD_1	32.4	244	300	310	2.30e-20	88.2
k141_37549_45	SARG|gb|ADZ12699.1|ARO:3005091|RanA	33.7	249	260	258	7.31e-40	137
k141_37549_45	SARG|gi|895981299|ref|WP_049056431.1|	36.9	241	260	648	1.11e-39	144
k141_37549_45	SARG|gi|823281237|ref|WP_047037467.1|	36.9	241	260	648	1.11e-39	144
k141_37549_45	SARG|gi|895967513|ref|WP_049046752.1|	36.9	241	260	648	1.11e-39	144
k141_37549_45	SARG|gi|779903733|ref|WP_045374054.1|	36.9	241	260	648	1.11e-39	144
k141_37549_45	SARG|gi|505180394|ref|WP_015367496.1|	37.4	238	260	648	1.11e-39	144
k141_37549_45	SARG|gi|823326845|ref|WP_047080664.1|	37.4	238	260	648	1.52e-39	144
k141_37549_45	SARG|gi|695793471|ref|WP_032707680.1|	37.4	238	260	648	1.52e-39	144
k141_37549_45	SARG|gi|823302270|ref|WP_047057473.1|	37.4	238	260	648	2.09e-39	143
k141_37549_45	SARG|gi|976146774|ref|WP_059305359.1|	37.4	238	260	648	2.09e-39	143
k141_37549_58	megares|MEG_2865|Drugs|Phenicol|Chloramphenicol_hydrolase|ESTD_1	34.4	227	294	310	1.10e-35	129
k141_37549_68	SARG|P42332	32.1	237	307	306	8.64e-27	105
k141_37549_68	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	32.1	237	307	306	8.64e-27	105
k141_37549_68	SARG|gi|510143239|gb|AGN36970.1|	32.1	237	307	313	9.75e-27	105
k141_37549_68	SARG|ABB80128	32.1	237	307	306	1.20e-26	105
k141_37549_68	SARG|gi|542061059|gb|ERI11611.1|	31.5	238	307	316	1.01e-25	103
k141_37549_68	SARG|gi|507044560|ref|WP_016115614.1|	31.1	228	307	306	2.26e-25	102
k141_37549_68	SARG|gi|500194536|ref|WP_011867743.1|	31.2	237	307	306	8.32e-25	100
k141_37549_68	SARG|gi|447195835|ref|WP_001273091.1|	31.6	237	307	306	1.59e-24	99.8
k141_37549_68	SARG|gi|895736250|emb|COF64653.1|	30.9	236	307	309	1.67e-24	99.8
k141_37549_68	SARG|gi|446110087|ref|WP_000187942.1|	30.9	236	307	309	1.67e-24	99.8
k141_37549_69	NCBI|AAD44693.1|1|1|mtrA_Ngon|mtrA_Ngon||1|EFFLUX|EFFLUX|efflux_transporter_MtrCDE_transcriptional_activator_MtrA|AMR|efflux	26.3	80	397	301	1.91e-07	51.2
k141_37549_134	SARG|gi|764446018|ref|WP_044369325.1|	27.7	220	258	605	1.64e-15	74.7
k141_37549_134	SARG|gi|695887424|ref|WP_032788534.1|	27.7	220	258	605	2.22e-15	74.3
k141_37549_134	SARG|gi|664180077|ref|WP_030714054.1|	27.7	220	258	605	2.22e-15	74.3
k141_37549_134	SARG|gi|1033151784|ref|WP_064457526.1|	28.4	218	258	614	3.01e-15	73.9
k141_37549_134	SARG|gi|987887954|ref|WP_060953374.1|	28.4	218	258	614	3.01e-15	73.9
k141_37549_134	SARG|gi|664304639|ref|WP_030834011.1|	28.4	218	258	614	3.01e-15	73.9
k141_37549_134	SARG|gi|1011069317|ref|WP_062010695.1|	28.4	218	258	614	3.01e-15	73.9
k141_37549_134	SARG|gi|1045390184|ref|WP_065479071.1|	27.3	220	258	605	4.04e-15	73.6
k141_37549_134	SARG|gi|663330365|ref|WP_030329892.1|	28.6	217	258	607	5.46e-15	73.2
k141_37549_134	SARG|gi|664042835|ref|WP_030582300.1|	27.6	217	258	604	9.92e-15	72.4
k141_37549_142	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	30.7	238	257	343	2.59e-26	103
k141_37549_143	SARG|gi|542061059|gb|ERI11611.1|	32.5	243	237	316	2.80e-25	100
k141_37549_143	SARG|gb|CDO61516.1|ARO:3003949|efrB	28.4	162	237	362	3.63e-09	55.1
k141_37549_148	SARG|gi|695731408|ref|WP_032657917.1|	34.5	232	251	646	3.38e-31	120
k141_37549_148	SARG|gi|896088003|ref|WP_049126277.1|	34.5	232	251	646	3.38e-31	120
k141_37549_148	SARG|gi|1028180030|ref|WP_063927084.1|	34.5	232	251	646	3.38e-31	120
k141_37549_148	SARG|gi|798862580|ref|WP_045895455.1|	34.5	232	251	646	3.38e-31	120
k141_37549_148	SARG|gi|817652267|ref|WP_046618460.1|	34.2	234	251	646	4.61e-31	119
k141_37549_148	SARG|gi|798872593|ref|WP_045897770.1|	34.2	234	251	646	4.61e-31	119
k141_37549_148	SARG|gi|556463948|ref|WP_023315739.1|	34.5	232	251	646	4.61e-31	119
k141_37549_148	SARG|gi|695627534|ref|WP_032608952.1|	34.2	234	251	646	4.61e-31	119
k141_37549_148	SARG|gi|915701375|ref|WP_050871437.1|	34.2	234	251	646	4.61e-31	119
k141_37549_148	SARG|gi|779850732|ref|WP_045348329.1|	34.1	232	251	646	4.61e-31	119
k141_37549_151	SARG|gb|APB03219.1|ARO:3003986|TaeA	31.4	102	547	648	8.65e-08	53.9
k141_37549_162	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	37.3	201	226	231	3.66e-43	144
k141_37549_162	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	36.3	201	226	233	5.46e-43	144
k141_37549_162	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.7	218	226	219	4.15e-42	141
k141_37549_162	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.2	222	226	219	1.00e-36	127
k141_37549_162	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.2	222	226	219	1.41e-36	127
k141_37549_162	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.2	222	226	220	1.45e-36	127
k141_37549_162	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.2	222	226	220	2.05e-36	126
k141_37549_162	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.8	222	226	220	4.49e-35	123
k141_37549_162	CARD|gb|AAG06465.1|ARO:3005063|cprR	35.3	221	226	223	6.83e-35	122
k141_37549_162	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	36.2	218	226	225	1.01e-34	122
k141_37549_163	CARD|gb|ABD30512.1|ARO:3000839|arlS	29.2	298	381	451	2.82e-36	136
k141_37549_163	CARD|gb|ADM92606.1|ARO:3000549|adeS	24.5	306	381	361	2.71e-20	90.1
k141_37549_163	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	28.2	216	381	364	1.75e-19	87.8
k141_37549_163	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	28.2	216	381	364	1.75e-19	87.8
k141_37549_163	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	28.4	215	381	364	3.62e-18	84.0
k141_37549_163	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	28.4	215	381	364	3.62e-18	84.0
k141_154267_45	SARG|gb|AAK76136.1|ARO:3000025|patB	36.5	586	612	588	3.37e-117	360
k141_154267_45	SARG|gb|AYV52072.1|ARO:3002882|lmrD	37.7	522	612	664	9.32e-110	343
k141_154267_45	SARG|gb|AAC74000.1|ARO:3003950|msbA	36.2	516	612	582	1.63e-96	306
k141_154267_45	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	33.6	565	612	579	1.59e-85	277
k141_154267_45	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	31.6	570	612	579	4.36e-85	276
k141_154267_45	SARG|gi|928900436|ref|WP_053931243.1|	30.1	555	612	600	5.21e-85	276
k141_154267_45	SARG|gi|664579989|ref|WP_031094015.1|	30.1	555	612	601	5.33e-85	276
k141_154267_45	SARG|gi|947982677|ref|WP_056642336.1|	31.4	558	612	626	6.90e-85	276
k141_154267_45	SARG|gi|944152509|ref|WP_055644808.1|	31.1	557	612	616	7.63e-85	276
k141_154267_45	SARG|gi|639892676|ref|WP_024755698.1|	31.4	558	612	631	7.76e-85	276
k141_154267_46	SARG|gb|WP_104671188.1|ARO:3003948|efrA	34.8	572	575	575	3.17e-102	319
k141_154267_46	SARG|gb|AAK76137.1|ARO:3000024|patA	31.9	496	575	564	1.60e-72	241
k141_154267_46	SARG|gi|496018010|ref|WP_008742581.1|	27.9	556	575	623	4.18e-52	187
k141_154267_46	SARG|gi|917229923|ref|WP_051836635.1|	27.9	559	575	620	3.75e-51	184
k141_154267_46	SARG|gi|860594225|ref|WP_048475168.1|	27.5	559	575	620	7.10e-51	184
k141_154267_46	SARG|gi|1045390184|ref|WP_065479071.1|	27.3	560	575	605	1.08e-50	183
k141_154267_46	SARG|gi|926356413|ref|WP_053687351.1|	28.3	559	575	620	1.34e-50	183
k141_154267_46	SARG|gi|926345639|ref|WP_053677539.1|	28.3	559	575	620	1.34e-50	183
k141_154267_46	SARG|gi|926376632|ref|WP_053705806.1|	28.1	559	575	620	1.34e-50	183
k141_154267_46	SARG|gi|739906046|ref|WP_037756452.1|	27.7	556	575	620	1.85e-50	182
k141_74808_22	NCBI|WP_063856920.1|1|1|vanY-Pt|vanY-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_carboxypeptidase_VanY-Pt|AMR|glycopeptide	39.0	146	219	296	1.29e-24	97.4
k141_74808_22	NCBI|WP_063856916.1|1|1|vanY-Pt|vanY-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_carboxypeptidase_VanY-Pt|AMR|glycopeptide	39.0	146	219	299	1.35e-24	97.4
k141_74808_22	SARG|AAY52007	39.0	146	219	294	1.74e-24	97.1
k141_74808_22	SARG|gi|503204183|ref|WP_013438844.1|	34.5	194	219	303	1.45e-23	94.7
k141_74808_22	SARG|ACP19238	37.7	146	219	296	1.82e-23	94.4
k141_74808_22	megares|MEG_7597|Drugs|Glycopeptide|VanA-type_accessory_protein|VANYA_1	37.7	146	219	296	1.82e-23	94.4
k141_74808_22	SARG|AAA65958	37.7	146	219	303	2.02e-23	94.4
k141_74808_22	SARG|gi|309385867|gb|ADO66792.1|	37.7	146	219	305	2.08e-23	94.4
k141_74808_22	SARG|gi|816206780|gb|AKE81065.1|	37.7	146	219	327	2.83e-23	94.4
k141_74808_22	SARG|CAB61224	37.0	146	219	297	3.57e-23	93.6
k141_74808_23	SARG|AF155139.2.gene4.p01	30.6	255	291	293	6.26e-31	116
k141_74808_23	SARG|gi|491689491|ref|WP_005545369.1|	30.4	250	291	287	2.10e-30	114
k141_74808_23	SARG|gi|1025843957|ref|WP_063576302.1|	32.3	229	291	287	1.17e-25	102
k141_74808_23	NCBI|WP_107309513.1|1|1|vanY-M|vanY-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_carboxypeptidase_VanY-M|AMR|glycopeptide	30.9	204	291	287	4.31e-24	97.8
k141_74808_23	SARG|FJ349556.1.gene4.p01	31.9	188	291	233	5.75e-24	96.3
k141_74808_23	SARG|gi|503204183|ref|WP_013438844.1|	31.7	180	291	303	2.06e-23	96.3
k141_74808_23	SARG|ACP19238	40.7	118	291	296	2.55e-23	95.9
k141_74808_23	megares|MEG_7597|Drugs|Glycopeptide|VanA-type_accessory_protein|VANYA_1	40.7	118	291	296	2.55e-23	95.9
k141_74808_23	SARG|AAA65958	40.7	118	291	303	2.85e-23	95.9
k141_74808_23	SARG|gi|309385867|gb|ADO66792.1|	40.7	118	291	305	2.94e-23	95.9
k141_74808_30	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	34.1	135	402	639	2.61e-13	70.5
k141_74808_31	SARG|L42544.gene.p01	27.9	663	694	651	5.06e-79	264
k141_74808_31	SARG|NP_348076	27.8	672	694	652	7.20e-79	263
k141_74808_31	SARG|AAV80410	27.9	663	694	651	9.82e-79	263
k141_74808_31	SARG|YP_002850805	27.2	659	694	652	5.33e-74	250
k141_74808_31	SARG|ZP_02952732	27.1	661	694	652	1.42e-72	246
k141_74808_31	SARG|ZP_02632674	27.1	661	694	660	1.67e-72	246
k141_74808_31	SARG|L20800.gene.p01	27.1	661	694	652	2.74e-72	246
k141_74808_31	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.1	657	694	639	1.08e-71	244
k141_74808_31	SARG|AY485126.gene.p01	25.7	685	694	639	1.50e-71	243
k141_74808_31	SARG|AAO42740	26.5	657	694	639	5.57e-71	242
k141_74808_35	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	53.8	1224	1252	1162	0.0	1214
k141_74808_35	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	49.7	1264	1252	1186	0.0	1140
k141_74808_35	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	49.7	1264	1252	1186	0.0	1140
k141_37692_16	megares|MEG_727|Drugs|beta-lactam|Class_C_betalactamases|AMPC_1	33.7	403	409	415	6.10e-79	248
k141_37692_22	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	27.4	310	483	451	1.66e-12	68.2
k141_37692_22	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	27.2	312	483	481	2.38e-12	67.8
k141_37692_26	SARG|gi|446048013|ref|WP_000125868.1|	23.0	217	515	648	6.16e-12	67.0
k141_37692_90	SARG|P13079	26.2	221	284	299	1.36e-13	68.6
k141_37692_90	SARG|gb|ANZ79476.1|ARO:3003908|Erm(47)	31.2	138	284	246	1.77e-12	64.7
k141_37692_92	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.9	528	645	655	1.00e-104	330
k141_37692_92	SARG|gb|AKA86814|ARO:3003746|optrA	37.9	528	645	655	1.00e-104	330
k141_37692_92	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.9	528	645	655	7.66e-104	328
k141_37692_92	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.9	528	645	655	7.66e-104	328
k141_37692_92	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.9	528	645	655	7.66e-104	328
k141_37692_92	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.9	528	645	655	7.66e-104	328
k141_37692_92	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.7	528	645	655	1.08e-103	328
k141_37692_92	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.9	528	645	655	1.51e-103	327
k141_37692_92	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.9	528	645	655	1.51e-103	327
k141_37692_92	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.9	528	645	655	1.51e-103	327
k141_37692_172	SARG|Q7N0B9	33.8	272	273	272	3.43e-32	118
k141_37692_172	SARG|Q2NWE3	34.5	261	273	273	3.51e-32	118
k141_37692_172	SARG|ZP_04637931	32.8	274	273	269	4.49e-32	118
k141_37692_172	SARG|ZP_04612440	32.4	272	273	272	6.72e-32	117
k141_37692_172	SARG|YP_001007833	33.5	272	273	272	6.72e-32	117
k141_37692_172	SARG|YP_001480516	33.9	277	273	274	9.83e-32	117
k141_37692_172	SARG|ZP_04623431	32.4	272	273	272	1.32e-31	117
k141_37692_172	SARG|YP_002931998	32.2	276	273	272	1.84e-31	116
k141_37692_172	SARG|ZP_04632979	31.5	270	273	272	1.84e-31	116
k141_37692_172	SARG|ZP_04616832	33.1	272	273	274	1.93e-31	116
k141_207278_53	NCBI|WP_128268231.1|1|1|mecC2|mecC2|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC2|AMR|beta-lactam	25.1	467	747	665	2.12e-14	75.9
k141_207278_55	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	37.0	462	467	481	5.11e-86	271
k141_207278_55	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	36.8	459	467	451	6.20e-86	270
k141_207278_55	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	37.0	460	467	451	6.83e-85	267
k141_207278_74	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	35.8	232	366	355	1.46e-36	134
k141_207278_74	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	35.8	232	366	355	1.46e-36	134
k141_207278_74	SARG|ACM47285	35.8	232	366	363	1.71e-36	134
k141_207278_74	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	35.3	232	366	355	2.04e-34	129
k141_207278_74	SARG|BAE96115	35.3	232	366	355	2.04e-34	129
k141_207278_74	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	34.5	232	366	356	3.98e-33	125
k141_207278_74	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	34.1	232	366	356	5.42e-32	122
k141_207278_74	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	34.1	232	366	356	5.42e-32	122
k141_207278_74	NCBI|WP_063856871.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.9	259	366	346	4.32e-30	117
k141_207278_74	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	35.3	187	366	209	1.68e-24	98.6
k141_207278_86	SARG|P42332	38.2	217	305	306	4.96e-46	156
k141_207278_86	SARG|ABB80128	38.2	217	305	306	6.97e-46	156
k141_207278_86	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	37.8	217	305	306	1.38e-45	155
k141_207278_86	SARG|gi|510143239|gb|AGN36970.1|	37.8	217	305	313	1.64e-45	155
k141_207278_86	SARG|AAD21213	37.8	217	305	306	3.83e-45	154
k141_207278_86	SARG|gi|542061059|gb|ERI11611.1|	30.7	309	305	316	6.88e-45	154
k141_207278_86	SARG|gi|500194536|ref|WP_011867743.1|	32.7	284	305	306	7.56e-45	153
k141_207278_86	SARG|ZP_04081918	32.3	303	305	306	8.79e-43	148
k141_207278_86	SARG|gi|447195835|ref|WP_001273091.1|	36.9	217	305	306	1.23e-42	147
k141_207278_86	SARG|gi|445996732|ref|WP_000074587.1|	32.7	281	305	309	1.86e-42	147
k141_207278_95	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	36.0	225	297	307	1.33e-38	137
k141_207278_95	SARG|gi|542061059|gb|ERI11611.1|	27.8	302	297	316	4.32e-29	112
k141_207278_95	SARG|gi|500194536|ref|WP_011867743.1|	30.7	228	297	306	2.61e-27	107
k141_207278_95	SARG|P42332	28.1	299	297	306	6.99e-27	105
k141_207278_95	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	28.1	299	297	306	6.99e-27	105
k141_207278_95	SARG|gi|510143239|gb|AGN36970.1|	28.1	299	297	313	7.89e-27	105
k141_207278_95	SARG|ABB80128	28.1	299	297	306	9.71e-27	105
k141_207278_95	SARG|gi|446026113|ref|WP_000103968.1|	26.7	300	297	306	9.71e-27	105
k141_207278_95	SARG|ZP_04081918	28.0	300	297	306	1.35e-26	105
k141_207278_95	SARG|gi|507044560|ref|WP_016115614.1|	26.7	300	297	306	2.60e-26	104
k141_207278_98	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	32.4	173	583	255	3.85e-14	71.6
k141_207278_98	SARG|ZP_04081918	32.1	140	583	306	1.46e-10	61.6
k141_207278_98	SARG|gi|447195835|ref|WP_001273091.1|	32.1	140	583	306	1.96e-10	61.2
k141_207278_98	SARG|gi|447195836|ref|WP_001273092.1|	31.4	140	583	306	4.67e-10	60.1
k141_207278_114	megares|MEG_4107|Drugs|MLS|23S_rRNA_methyltransferases|MYRA_1	37.8	201	274	283	2.87e-34	124
k141_207278_114	megares|MEG_4106|Drugs|MLS|23S_rRNA_methyltransferases|MYRA_1	35.0	203	274	295	2.35e-29	111
k141_207278_114	SARG|gb|BAA03674.1|ARO:3001300|myrA	35.0	203	274	295	2.35e-29	111
k141_207278_114	SARG|gb|AJD73064.1|ARO:3001301|RlmA(II)	29.7	273	274	282	6.91e-29	110
k141_207278_114	SARG|gb|AAS79458.1|ARO:3001302|chrB	35.8	190	274	280	6.83e-28	107
k141_207278_114	SARG|gb|AAD12162.1|ARO:3001299|tlrB	35.4	195	274	280	9.74e-27	104
k141_207278_114	SARG|gb|CAB37345.2|ARO:3004592|erm(32)	35.4	195	274	280	1.36e-26	103
k141_207278_204	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	40.6	219	244	343	4.09e-49	163
k141_207278_204	SARG|gb|AAA26793|ARO:3003748|oleC	38.2	220	244	325	7.55e-45	152
k141_207278_204	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	38.2	220	244	325	7.55e-45	152
k141_207278_204	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	36.6	205	244	293	7.63e-40	138
k141_207278_204	SARG|gi|446026113|ref|WP_000103968.1|	36.9	214	244	306	1.93e-35	127
k141_207278_204	SARG|gi|507044560|ref|WP_016115614.1|	36.9	214	244	306	3.80e-35	126
k141_207278_204	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	30.4	230	244	351	2.01e-24	98.6
k141_207278_204	SARG|gb|AAR96051.1|ARO:3002894|otrC	30.4	230	244	351	2.79e-24	98.2
k141_207278_204	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	27.5	178	244	505	3.95e-07	49.3
k141_207278_204	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	27.9	172	244	504	9.79e-06	45.1
k141_38455_8	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	44.6	224	229	231	1.35e-55	176
k141_38455_8	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	42.2	225	229	228	5.60e-54	172
k141_38455_8	CARD|gb|ATC67679.1|ARO:3000838|arlR	38.9	221	229	219	2.43e-53	170
k141_38455_8	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	36.7	226	229	229	7.56e-49	159
k141_38455_8	CARD|gb|AAD51348.1|ARO:3003066|smeR	38.5	226	229	229	1.20e-47	155
k141_38455_8	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.9	227	229	219	1.82e-41	139
k141_38455_8	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.9	227	229	220	1.87e-41	139
k141_38455_8	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.9	227	229	220	5.25e-41	138
k141_38455_8	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.5	227	229	219	1.44e-40	137
k141_38455_8	CARD|gb|ADM92605.1|ARO:3000553|adeR	37.6	226	229	247	4.28e-40	137
k141_38455_9	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	27.4	274	505	370	5.37e-28	114
k141_38455_9	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	25.9	286	505	365	2.35e-25	106
k141_38455_9	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	28.5	281	505	386	5.30e-23	99.8
k141_38455_9	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	28.5	281	505	386	5.30e-23	99.8
k141_38455_9	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	29.0	279	505	357	1.25e-22	98.2
k141_38455_9	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	29.0	279	505	357	1.25e-22	98.2
k141_38455_9	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	28.7	261	505	359	5.76e-22	96.3
k141_38455_9	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	28.7	324	505	386	7.84e-22	96.3
k141_38455_9	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	28.7	324	505	386	7.84e-22	96.3
k141_38455_9	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	28.1	281	505	384	1.04e-21	95.9
k141_38455_27	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	44.1	1035	1051	1024	0.0	924
k141_38455_27	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	44.1	1035	1051	1024	0.0	924
k141_38455_27	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	43.8	1035	1051	1024	0.0	917
k141_38455_27	SARG|gb|CAA53189|ARO:3000521|mupA	43.8	1035	1051	1024	0.0	917
k141_38455_27	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	45.1	1022	1051	1033	0.0	915
k141_38455_27	SARG|gb|AEY83581|ARO:3000510|mupB	45.1	1022	1051	1033	0.0	915
k141_38455_27	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	36.1	1112	1051	1107	4.31e-225	671
k141_38455_27	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	36.1	1112	1051	1107	4.31e-225	671
k141_38455_59	SARG|gb|AAK76136.1|ARO:3000025|patB	36.1	574	578	588	1.62e-114	352
k141_38455_59	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.9	501	578	664	8.11e-99	313
k141_38455_59	SARG|gb|CDO61516.1|ARO:3003949|efrB	48.6	333	578	362	1.94e-96	297
k141_38455_59	SARG|gi|1033217078|gb|OAR27197.1|	32.9	575	578	601	1.31e-88	285
k141_38455_59	SARG|gi|944009777|ref|WP_055601444.1|	31.3	584	578	628	1.03e-86	280
k141_38455_59	SARG|gi|695865802|ref|WP_032778631.1|	30.4	579	578	605	3.21e-86	278
k141_38455_59	SARG|gi|517347347|ref|WP_018522839.1|	30.3	571	578	601	4.08e-86	278
k141_38455_59	SARG|gi|695842130|ref|WP_032755430.1|	30.6	571	578	603	8.41e-86	277
k141_38455_59	SARG|gi|951183771|ref|WP_057661487.1|	30.7	579	578	603	8.41e-86	277
k141_38455_59	SARG|gi|827013130|ref|WP_047175495.1|	30.6	579	578	603	8.41e-86	277
k141_38455_60	SARG|gb|WP_104671188.1|ARO:3003948|efrA	37.4	545	575	575	5.68e-114	350
k141_38455_60	SARG|gb|AAK76137.1|ARO:3000024|patA	33.1	571	575	564	9.06e-94	297
k141_38455_60	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	30.1	495	575	574	1.68e-58	204
k141_38455_60	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	33.7	392	575	579	4.92e-58	202
k141_38455_60	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	33.9	392	575	579	4.81e-57	200
k141_38455_60	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	26.5	585	575	579	1.00e-50	182
k141_38455_60	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	27.5	586	575	579	1.38e-50	182
k141_38455_60	SARG|gi|948137056|ref|WP_056795395.1|	33.1	393	575	602	8.97e-49	177
k141_38455_60	SARG|gi|662754041|ref|WP_030125200.1|	32.3	393	575	601	4.33e-48	176
k141_38455_60	SARG|gb|AAK76136.1|ARO:3000025|patB	27.5	487	575	588	1.76e-47	174
k141_38455_63	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	37.6	221	235	307	8.44e-47	156
k141_38455_63	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	32.7	220	235	293	2.08e-40	139
k141_38455_63	SARG|gi|500194536|ref|WP_011867743.1|	34.3	213	235	306	2.08e-35	126
k141_38455_71	SARG|gi|639209604|ref|WP_024547784.1|	28.7	223	519	648	2.98e-19	90.1
k141_38455_76	NCBI|BAB64566.1|1|1|bexA|bexA|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_MATE_transporter_BexA|AMR|efflux	21.0	371	467	443	8.92e-16	78.2
k141_86297_3	megares|MEG_1680|Drugs|MLS|23S_rRNA_methyltransferases|CFR_1	67.3	52	58	416	3.11e-21	83.2
k141_86297_124	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	28.6	203	549	255	8.41e-24	99.8
k141_86297_124	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	29.3	232	549	574	1.80e-21	97.1
k141_86297_124	SARG|gi|542061059|gb|ERI11611.1|	28.7	209	549	316	1.08e-20	92.0
k141_86297_124	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	31.1	219	549	343	1.16e-20	92.4
k141_86297_124	SARG|P42332	30.4	194	549	306	1.26e-20	91.7
k141_86297_124	SARG|ABB80128	30.4	194	549	306	1.26e-20	91.7
k141_86297_124	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	30.4	194	549	306	1.26e-20	91.7
k141_86297_124	SARG|gi|510143239|gb|AGN36970.1|	30.4	194	549	313	1.40e-20	91.7
k141_86297_124	SARG|gi|500448961|gb|EOP61695.1|	28.2	195	549	306	3.11e-20	90.5
k141_86297_124	SARG|YP_001373621	29.4	197	549	318	9.08e-20	89.4
k141_234968_33	SARG|gi|491270241|ref|WP_005128370.1|	44.1	236	234	648	9.46e-59	195
k141_234968_33	SARG|gi|696368937|ref|WP_032943949.1|	43.8	235	234	648	2.57e-58	194
k141_234968_33	SARG|gi|922960663|ref|WP_053388845.1|	43.8	235	234	648	2.57e-58	194
k141_234968_33	SARG|gi|1045891604|ref|WP_065554100.1|	43.8	235	234	648	3.58e-58	193
k141_234968_33	SARG|gi|507082903|ref|WP_016153652.1|	43.8	235	234	648	3.58e-58	193
k141_234968_33	SARG|Q83LR7	43.6	234	234	648	3.58e-58	193
k141_234968_33	SARG|gi|647325472|ref|WP_025760953.1|	43.6	234	234	648	3.58e-58	193
k141_234968_33	SARG|gi|647323678|ref|WP_025760497.1|	43.6	234	234	648	3.58e-58	193
k141_234968_33	SARG|gi|696361545|ref|WP_032936694.1|	43.8	235	234	648	3.58e-58	193
k141_234968_33	SARG|gi|851902043|ref|WP_048212057.1|	43.6	236	234	648	3.58e-58	193
k141_188562_14	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	22.7	699	801	1033	2.98e-30	127
k141_188562_14	SARG|gb|AEY83581|ARO:3000510|mupB	22.7	699	801	1033	2.98e-30	127
k141_188562_14	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	21.6	862	801	1024	1.09e-28	122
k141_188562_14	SARG|gb|CAA53189|ARO:3000521|mupA	21.6	862	801	1024	1.09e-28	122
k141_188562_14	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	21.7	848	801	1024	2.50e-28	121
k141_188562_14	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	21.7	848	801	1024	2.50e-28	121
k141_188562_14	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	21.8	913	801	1107	1.22e-20	96.7
k141_188562_14	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	21.8	913	801	1107	1.22e-20	96.7
k141_71233_4	SARG|KF478993.1.gene3.p01	30.3	347	335	346	4.41e-36	132
k141_13813_63	SARG|YP_302230	20.5	380	465	451	1.15e-26	110
k141_13813_63	SARG|gi|505177635|ref|WP_015364737.1|	19.7	380	465	451	7.11e-26	108
k141_13813_63	SARG|ZP_04679156	20.8	380	465	451	3.23e-25	106
k141_13813_68	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	25.7	782	880	1024	7.44e-74	261
k141_13813_68	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	25.7	782	880	1024	7.44e-74	261
k141_13813_68	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	25.7	782	880	1024	2.56e-73	259
k141_13813_68	SARG|gb|CAA53189|ARO:3000521|mupA	25.7	782	880	1024	2.56e-73	259
k141_13813_76	SARG|gi|657888313|ref|WP_029592374.1|	38.1	318	881	648	1.82e-52	193
k141_13813_76	SARG|gi|639225329|ref|WP_024561799.1|	37.7	318	881	648	3.35e-52	192
k141_13813_76	SARG|gi|639218559|ref|WP_024556062.1|	37.7	318	881	648	3.35e-52	192
k141_13813_76	SARG|gi|1033064422|ref|WP_064375412.1|	37.3	316	881	648	5.15e-51	189
k141_13813_76	SARG|gi|751930065|ref|WP_041144773.1|	37.2	317	881	648	6.97e-51	189
k141_13813_76	SARG|gi|639216333|ref|WP_024554080.1|	36.9	317	881	648	9.43e-51	188
k141_13813_76	SARG|gi|938460528|ref|WP_054624864.1|	37.1	315	881	647	2.31e-50	187
k141_13813_76	SARG|gi|823326845|ref|WP_047080664.1|	38.0	316	881	648	2.34e-50	187
k141_13813_76	SARG|gi|504542119|ref|WP_014729221.1|	36.8	315	881	647	4.22e-50	186
k141_13813_76	SARG|gi|655997348|ref|WP_029038923.1|	36.8	315	881	647	4.22e-50	186
k141_13813_110	SARG|gb|WP_104671188.1|ARO:3003948|efrA	28.3	230	333	575	1.14e-16	79.7
k141_13813_110	SARG|gb|CDO61516.1|ARO:3003949|efrB	28.7	157	333	362	2.13e-11	63.2
k141_13813_114	SARG|gb|WP_011094382.1|ARO:3006903|CAR-1	30.5	128	216	342	1.99e-11	61.2
k141_13813_114	NCBI|WP_015048279.1|1|1|blaSAM-1|blaSAM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_SAM-1|AMR|beta-lactam	31.4	118	216	295	3.52e-10	57.4
k141_13813_114	SARG|gb|WP_122630831.1|ARO:3006864|CRD3-1	30.6	108	216	303	6.70e-10	56.6
k141_13813_114	SARG|gb|WP_122630825.1|ARO:3006873|EAM-1	25.7	140	216	318	7.07e-10	56.6
k141_13813_114	NCBI|WP_219860712.1|1|1|blaB3SU1-1|blaB3SU1|hydrolase|2|CEPHALOSPORIN|beta-lactam|subclass_B3_metallo-beta-lactamase_B3SU1-1|AMR|beta-lactam	27.3	165	216	303	3.43e-08	51.6
k141_146845_17	SARG|P42332	41.7	302	301	306	1.98e-70	219
k141_146845_17	SARG|gi|488068784|ref|WP_002140181.1|	42.7	302	301	309	3.06e-70	219
k141_146845_17	SARG|gi|507023808|ref|WP_016095885.1|	42.4	302	301	309	4.32e-70	218
k141_146845_17	SARG|gi|895808656|emb|COR83787.1|	42.4	302	301	309	4.32e-70	218
k141_146845_17	SARG|ABB80128	41.7	302	301	306	5.59e-70	218
k141_146845_17	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	41.4	302	301	306	5.59e-70	218
k141_146845_17	SARG|gi|510143239|gb|AGN36970.1|	41.4	302	301	313	6.88e-70	218
k141_146845_17	SARG|gi|488067981|ref|WP_002139378.1|	42.1	302	301	309	8.63e-70	218
k141_146845_17	SARG|gi|445996724|ref|WP_000074579.1|	42.7	302	301	309	1.22e-69	217
k141_146845_17	SARG|gi|445996729|ref|WP_000074584.1|	42.4	302	301	309	1.22e-69	217
k141_146845_31	SARG|gi|493394434|ref|WP_006350564.1|	40.8	238	619	602	6.63e-43	162
k141_146845_31	SARG|gi|664556405|ref|WP_031071225.1|	38.4	250	619	602	1.23e-42	161
k141_146845_31	SARG|gi|748767925|ref|WP_040019608.1|	39.8	236	619	623	2.12e-42	160
k141_146845_31	SARG|gi|663350985|ref|WP_030349761.1|	38.4	250	619	613	6.49e-42	159
k141_146845_31	SARG|gi|516795764|ref|WP_018105258.1|	39.0	236	619	601	1.43e-41	158
k141_146845_31	SARG|gi|943896259|ref|WP_055534530.1|	38.4	250	619	601	1.43e-41	158
k141_146845_31	SARG|gi|926400371|ref|WP_053728483.1|	38.2	251	619	603	2.71e-41	157
k141_146845_31	SARG|gi|1011069317|ref|WP_062010695.1|	37.4	262	619	614	4.13e-41	157
k141_146845_31	SARG|gi|1033151784|ref|WP_064457526.1|	37.4	262	619	614	5.62e-41	156
k141_146845_31	SARG|gi|664304639|ref|WP_030834011.1|	37.4	262	619	614	5.62e-41	156
k141_146845_32	SARG|gb|AAC74000.1|ARO:3003950|msbA	35.9	306	630	582	9.25e-50	181
k141_146845_32	SARG|gi|664556405|ref|WP_031071225.1|	30.4	319	630	602	2.04e-37	146
k141_146845_32	SARG|gb|WP_104671188.1|ARO:3003948|efrA	34.0	244	630	575	3.21e-36	142
k141_146845_32	SARG|gi|664244930|ref|WP_030776974.1|	29.8	309	630	601	4.07e-36	142
k141_146845_32	SARG|gi|663350985|ref|WP_030349761.1|	28.4	313	630	613	4.50e-36	142
k141_146845_32	SARG|gi|748767925|ref|WP_040019608.1|	29.5	305	630	623	6.57e-36	142
k141_146845_32	SARG|gi|944470764|ref|WP_055701183.1|	34.3	289	630	601	1.35e-35	140
k141_146845_32	SARG|gi|943909899|ref|WP_055545300.1|	30.4	319	630	601	1.82e-35	140
k141_146845_32	SARG|gi|493394434|ref|WP_006350564.1|	28.8	312	630	602	2.47e-35	140
k141_146845_32	SARG|gi|1011969930|ref|WP_062776015.1|	30.7	319	630	601	3.30e-35	139
k141_247343_16	SARG|gi|976150171|ref|WP_059308384.1|	32.9	255	275	646	1.44e-37	139
k141_247343_16	SARG|gi|974588181|ref|WP_059178476.1|	34.2	240	275	646	5.10e-37	137
k141_247343_16	SARG|YP_001176128	34.2	240	275	646	6.99e-37	137
k141_247343_16	SARG|gi|749017716|ref|WP_040076354.1|	32.7	254	275	646	9.58e-37	136
k141_247343_16	SARG|gi|992390012|ref|WP_061077002.1|	36.4	239	275	648	4.20e-35	132
k141_247343_16	SARG|gi|968563772|ref|WP_058587854.1|	36.6	238	275	648	7.86e-35	131
k141_247343_16	SARG|gi|757782629|ref|WP_043001213.1|	36.6	238	275	648	7.86e-35	131
k141_247343_16	SARG|gi|763407609|ref|WP_044264203.1|	36.6	238	275	648	7.86e-35	131
k141_247343_16	SARG|gi|754927849|ref|WP_042284850.1|	36.6	238	275	648	7.86e-35	131
k141_247343_16	SARG|gi|817104523|ref|WP_046477871.1|	36.6	238	275	648	1.47e-34	130
k141_247343_30	SARG|gi|917229923|ref|WP_051836635.1|	30.9	557	727	620	9.68e-70	239
k141_247343_30	SARG|gi|926351744|ref|WP_053683383.1|	31.1	557	727	648	6.24e-69	237
k141_247343_30	SARG|gi|948137056|ref|WP_056795395.1|	29.8	557	727	602	9.06e-69	236
k141_247343_30	SARG|gi|496018010|ref|WP_008742581.1|	30.0	557	727	623	1.93e-68	235
k141_247343_30	SARG|gi|919568551|ref|WP_052871170.1|	31.1	557	727	620	2.52e-68	235
k141_247343_30	SARG|gi|921231571|ref|WP_053176464.1|	30.9	557	727	620	6.68e-68	234
k141_247343_30	SARG|gi|917172177|ref|WP_051778889.1|	30.9	557	727	620	9.25e-68	233
k141_247343_30	SARG|gi|695842130|ref|WP_032755430.1|	29.3	557	727	603	1.26e-67	233
k141_247343_30	SARG|gi|917166849|ref|WP_051773561.1|	30.3	557	727	620	1.77e-67	233
k141_247343_30	SARG|gi|917155568|ref|WP_051762280.1|	30.3	557	727	620	2.45e-67	232
k141_247343_31	SARG|gb|AAC74000.1|ARO:3003950|msbA	40.9	257	733	582	1.63e-48	179
k141_247343_31	SARG|gi|917203192|ref|WP_051809904.1|	29.0	563	733	620	8.37e-47	175
k141_247343_31	SARG|gb|AYV52072.1|ARO:3002882|lmrD	39.0	259	733	664	2.63e-46	174
k141_247343_31	SARG|gi|772774655|ref|WP_045322518.1|	27.8	561	733	620	2.85e-46	173
k141_247343_31	SARG|gi|926376632|ref|WP_053705806.1|	27.4	574	733	620	3.87e-46	173
k141_247343_31	SARG|gi|695865802|ref|WP_032778631.1|	26.7	565	733	605	4.32e-46	172
k141_247343_31	SARG|gi|1045390184|ref|WP_065479071.1|	26.9	565	733	605	7.98e-46	172
k141_247343_31	SARG|gi|739906046|ref|WP_037756452.1|	27.3	568	733	620	1.32e-45	171
k141_247343_31	SARG|gi|764446018|ref|WP_044369325.1|	26.5	565	733	605	1.47e-45	171
k141_247343_31	SARG|gi|664180077|ref|WP_030714054.1|	26.5	565	733	605	1.47e-45	171
k141_247343_47	CARD|gb|AEX49906.1|ARO:3003583|basS	33.2	208	394	477	5.43e-19	87.4
k141_247343_47	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	23.3	232	394	357	1.34e-08	55.1
k141_247343_47	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	23.3	232	394	357	1.34e-08	55.1
k141_247343_48	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.3	230	234	231	1.34e-48	158
k141_247343_48	CARD|gb|ATC67679.1|ARO:3000838|arlR	37.2	223	234	219	3.38e-46	152
k141_247343_48	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.3	226	234	231	1.33e-42	143
k141_247343_48	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	34.5	226	234	228	2.44e-42	142
k141_247343_48	CARD|gb|AAG05188.1|ARO:3005068|ParR	34.8	221	234	235	1.83e-40	137
k141_247343_48	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	31.9	235	234	252	1.06e-32	118
k141_247343_68	SARG|gi|488053456|ref|WP_002124853.1|	36.6	224	320	309	5.80e-46	157
k141_247343_68	SARG|gi|488130770|ref|WP_002201978.1|	37.1	224	320	309	5.80e-46	157
k141_247343_68	SARG|gi|488067981|ref|WP_002139378.1|	36.6	224	320	309	8.15e-46	156
k141_247343_68	SARG|gi|447057509|ref|WP_001134765.1|	37.1	224	320	309	8.15e-46	156
k141_247343_68	SARG|gi|487936534|ref|WP_002010000.1|	36.6	224	320	309	8.15e-46	156
k141_247343_68	SARG|gi|447195835|ref|WP_001273091.1|	37.9	224	320	306	1.06e-45	156
k141_247343_68	SARG|gi|488068784|ref|WP_002140181.1|	36.2	224	320	309	1.14e-45	156
k141_247343_68	SARG|P42332	30.1	309	320	306	1.49e-45	155
k141_247343_68	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	30.1	309	320	306	1.49e-45	155
k141_247343_68	SARG|gi|507055561|ref|WP_016126482.1|	36.6	224	320	309	1.61e-45	155
k141_220813_14	SARG|DQ212986.1.gene3.p01	50.0	68	73	75	4.19e-14	59.7
k141_220813_24	SARG|gi|671541568|ref|WP_031525212.1|	29.2	219	275	648	1.10e-13	69.7
k141_220813_24	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	27.0	233	275	568	3.42e-13	68.2
k141_220813_24	SARG|gi|686386599|ref|WP_031903183.1|	28.9	201	275	488	4.25e-13	67.8
k141_220813_24	SARG|gi|580336413|gb|EVD62957.1|	28.2	209	275	478	1.85e-12	65.9
k141_220813_24	SARG|gi|686444151|ref|WP_031925491.1|	28.4	201	275	488	1.87e-12	65.9
k141_220813_24	SARG|gi|581672381|gb|EVQ77821.1|	27.9	201	275	394	2.14e-12	65.5
k141_220813_24	SARG|gi|587321226|gb|EWW03298.1|	27.9	201	275	413	2.23e-12	65.5
k141_220813_24	SARG|YP_001569068	27.9	201	275	488	2.51e-12	65.5
k141_220813_24	SARG|gi|686379454|ref|WP_031899389.1|	27.9	201	275	488	2.51e-12	65.5
k141_220813_24	SARG|gi|727749040|ref|WP_033861720.1|	27.9	201	275	488	2.51e-12	65.5
k141_220813_50	CARD|gb|CYF42523.1|ARO:3004047|kdpD	29.1	230	862	885	6.27e-20	94.4
k141_220813_50	CARD|gb|AEX49906.1|ARO:3003583|basS	25.8	233	862	477	3.24e-15	78.2
k141_220813_50	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	23.9	243	862	364	5.12e-13	70.5
k141_220813_50	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	23.9	243	862	364	5.12e-13	70.5
k141_220813_50	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	24.0	229	862	359	8.78e-13	69.7
k141_220813_52	CARD|gb|AAC75429.1|ARO:3000833|evgS	27.2	372	898	1197	6.02e-27	117
k141_220813_52	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	26.8	224	898	359	5.20e-14	73.6
k141_220813_52	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	31.8	107	898	231	4.35e-08	53.9
k141_220813_52	SARG|gb|AAG05187.1|ARO:3005067|ParS	23.3	223	898	428	7.58e-08	54.7
k141_220813_52	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	30.8	107	898	232	8.41e-07	50.1
k141_220813_54	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	28.6	105	642	231	2.29e-07	51.2
k141_221370_45	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	29.1	697	661	703	3.77e-75	254
k141_221370_58	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	24.4	275	335	346	1.34e-13	69.7
k141_221370_82	SARG|gb|AAC74000.1|ARO:3003950|msbA	31.2	375	661	582	1.13e-54	195
k141_221370_82	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	37.1	245	661	579	5.98e-43	162
k141_221370_82	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	31.2	346	661	579	5.15e-42	159
k141_221370_82	SARG|gb|CDO61516.1|ARO:3003949|efrB	32.8	274	661	362	1.08e-39	148
k141_221370_82	SARG|gb|WP_104671188.1|ARO:3003948|efrA	31.0	339	661	575	2.21e-39	152
k141_221370_82	SARG|gb|AAC75271.1|ARO:3003952|yojI	28.6	231	661	547	2.10e-16	81.6
k141_221370_82	NCBI|AKC61310.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	26.9	201	661	552	2.21e-06	49.7
k141_221370_82	megares|MEG_7256|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|TLRC_1	25.5	196	661	540	2.88e-06	49.3
k141_221370_126	SARG|gi|505420018|ref|WP_015607120.1|	33.2	549	756	603	5.84e-100	320
k141_221370_126	SARG|gi|695842130|ref|WP_032755430.1|	33.2	549	756	603	1.60e-99	318
k141_221370_126	SARG|gi|948137056|ref|WP_056795395.1|	32.0	550	756	602	4.29e-99	317
k141_221370_126	SARG|gi|764446018|ref|WP_044369325.1|	32.8	548	756	605	9.11e-99	317
k141_221370_126	SARG|gi|663330365|ref|WP_030329892.1|	32.8	549	756	607	9.61e-99	317
k141_221370_126	SARG|gi|926286457|ref|WP_053623344.1|	32.6	552	756	605	1.28e-98	316
k141_221370_126	SARG|gi|664538723|ref|WP_031054357.1|	32.6	552	756	605	1.28e-98	316
k141_221370_126	SARG|gi|663155409|ref|WP_030194633.1|	32.6	549	756	605	2.50e-98	315
k141_221370_126	SARG|gi|928900436|ref|WP_053931243.1|	32.1	551	756	600	3.07e-98	315
k141_221370_126	SARG|gi|1033217078|gb|OAR27197.1|	32.9	554	756	601	3.15e-98	315
k141_221370_140	SARG|NP_348076	24.7	669	693	652	1.01e-61	217
k141_221370_140	SARG|ZP_02632674	24.5	674	693	660	5.78e-61	215
k141_221370_140	SARG|ZP_02952732	24.6	668	693	652	4.76e-60	212
k141_221370_140	SARG|L20800.gene.p01	24.4	668	693	652	1.71e-59	211
k141_221370_140	SARG|YP_002850805	24.1	668	693	652	2.36e-59	210
k141_221370_140	SARG|AAV80410	24.0	675	693	651	6.05e-59	209
k141_221370_140	SARG|L42544.gene.p01	24.0	675	693	651	2.98e-58	207
k141_221370_140	SARG|AJ514254.gene.p01	23.6	673	693	640	2.51e-51	187
k141_221370_140	NCBI|WP_013646121.1|1|1|tet(O/W/32/O)|tet(O/W/32/O)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_mosaic_protein_Tet(O/W/32/O)|AMR|tetracycline	24.7	676	693	639	5.61e-50	184
k141_221370_140	SARG|ABF69686	24.4	676	693	639	1.43e-49	182
k141_221370_144	SARG|gb|AAK76137.1|ARO:3000024|patA	31.7	520	614	564	3.35e-77	254
k141_221370_144	SARG|gi|505420018|ref|WP_015607120.1|	31.0	513	614	603	1.22e-74	249
k141_221370_144	SARG|gi|695842130|ref|WP_032755430.1|	31.0	513	614	603	1.70e-74	248
k141_221370_144	SARG|gi|948137056|ref|WP_056795395.1|	31.2	519	614	602	1.71e-73	246
k141_221370_144	SARG|gi|648667297|ref|WP_026359044.1|	30.9	518	614	605	3.54e-73	245
k141_221370_144	SARG|gb|WP_104671188.1|ARO:3003948|efrA	31.5	530	614	575	6.91e-73	243
k141_221370_144	SARG|gi|748767925|ref|WP_040019608.1|	30.0	524	614	623	1.41e-72	244
k141_221370_144	SARG|gi|639148059|ref|WP_024490169.1|	29.8	526	614	602	3.39e-72	242
k141_221370_144	SARG|gi|739906046|ref|WP_037756452.1|	29.4	528	614	620	3.56e-72	243
k141_221370_144	SARG|gi|516574297|ref|WP_017949361.1|	29.9	528	614	620	3.56e-72	243
k141_221370_145	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	32.8	610	616	579	2.33e-86	279
k141_221370_145	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	32.3	610	616	579	3.26e-86	279
k141_221370_145	SARG|gi|664170108|ref|WP_030704355.1|	31.0	594	616	603	1.58e-78	259
k141_221370_145	SARG|gb|AAK76136.1|ARO:3000025|patB	31.1	591	616	588	2.18e-78	258
k141_221370_145	SARG|gi|501350226|ref|WP_012381861.1|	31.3	594	616	603	2.20e-78	259
k141_221370_145	SARG|gi|948137056|ref|WP_056795395.1|	30.9	596	616	602	3.00e-78	258
k141_221370_145	SARG|gi|928900436|ref|WP_053931243.1|	30.9	602	616	600	4.01e-78	258
k141_221370_145	SARG|gi|490068471|ref|WP_003970646.1|	31.3	594	616	603	4.29e-78	258
k141_221370_145	SARG|gi|664579989|ref|WP_031094015.1|	31.0	596	616	601	1.12e-77	257
k141_221370_145	SARG|gi|517381192|ref|WP_018555350.1|	30.7	599	616	602	2.23e-77	256
k141_221370_149	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	35.2	230	603	384	1.03e-36	140
k141_221370_149	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	35.2	230	603	384	1.03e-36	140
k141_221370_149	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	35.2	230	603	386	3.76e-36	138
k141_221370_149	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	35.2	230	603	386	3.76e-36	138
k141_221370_149	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	34.8	230	603	386	7.03e-36	137
k141_221370_149	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	34.8	230	603	386	7.03e-36	137
k141_221370_149	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	34.8	230	603	388	1.36e-35	137
k141_221370_149	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	34.8	230	603	388	1.36e-35	137
k141_221370_149	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	33.9	230	603	382	7.01e-34	132
k141_221370_149	NCBI|WP_063856731.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	33.9	230	603	382	7.01e-34	132
k141_221370_150	CARD|gb|ATC67679.1|ARO:3000838|arlR	42.8	229	240	219	1.31e-58	184
k141_221370_150	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	42.8	236	240	239	2.81e-54	173
k141_221370_150	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	40.1	232	240	228	4.59e-53	170
k141_221370_150	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.2	228	240	232	1.03e-52	169
k141_221370_150	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.2	228	240	232	1.03e-52	169
k141_221370_150	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	40.5	232	240	233	1.92e-50	163
k141_221370_150	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	40.1	227	240	231	8.13e-49	159
k141_221370_150	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	39.9	233	240	232	3.75e-47	155
k141_221370_150	CARD|gb|AAG05188.1|ARO:3005068|ParR	38.8	227	240	235	5.76e-47	154
k141_221370_150	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	39.5	233	240	232	7.48e-47	154
k141_221370_156	SARG|gb|ABA71733.1|ARO:3002972|vanTG	34.7	369	389	712	1.37e-53	187
k141_221370_156	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	34.6	370	389	712	2.91e-49	176
k141_221370_156	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	31.9	370	389	366	1.62e-47	164
k141_221370_156	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	32.3	368	389	711	2.91e-45	164
k141_221370_156	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	33.8	370	389	700	1.30e-44	162
k141_221370_156	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	33.1	369	389	700	4.17e-43	158
k141_221370_156	NCBI|WP_063856758.1|1|1|vanTc2|vanTc2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	32.5	369	389	706	6.50e-41	152
k141_221370_156	NCBI|WP_063856759.1|1|1|vanTc3|vanTc3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	32.2	369	389	700	1.60e-40	151
k141_221370_156	SARG|gi|498467693|ref|WP_010773049.1|	30.1	376	389	700	1.27e-36	140
k141_221370_156	SARG|AF162694.1.gene4.p01	29.3	375	389	698	1.08e-35	137
k141_126832_8	SARG|gi|498115003|ref|WP_010429159.1|	44.5	220	221	646	1.23e-52	178
k141_126832_8	SARG|gi|654544841|ref|WP_028012549.1|	44.5	220	221	646	1.71e-52	177
k141_126832_8	SARG|gi|896106549|ref|WP_049136608.1|	44.1	220	221	646	2.38e-52	177
k141_126832_8	SARG|gi|742378414|ref|WP_038857601.1|	43.6	220	221	647	4.65e-52	176
k141_126832_8	SARG|gi|895898290|ref|WP_048999361.1|	44.1	220	221	646	6.39e-52	176
k141_126832_8	SARG|gi|506220920|ref|WP_015740695.1|	43.6	220	221	647	6.46e-52	176
k141_126832_8	SARG|gi|639225329|ref|WP_024561799.1|	42.7	220	221	648	6.54e-52	176
k141_126832_8	SARG|gi|746253210|ref|WP_039301529.1|	42.7	220	221	648	6.54e-52	176
k141_126832_8	SARG|gi|1001720867|ref|WP_061274204.1|	42.7	220	221	648	6.54e-52	176
k141_126832_8	SARG|gi|639218559|ref|WP_024556062.1|	42.7	220	221	648	6.54e-52	176
k141_126832_25	SARG|gi|1004359922|gb|AMP42228.1|	25.9	436	604	639	1.06e-27	117
k141_126832_25	SARG|ABN80187	26.4	436	604	640	5.95e-27	114
k141_126832_25	SARG|ACI02041	25.6	434	604	639	1.38e-25	110
k141_126832_25	SARG|ACA23187	25.3	434	604	639	2.44e-25	109
k141_126832_25	SARG|gi|1004359892|gb|AMP42199.1|	25.6	434	604	639	4.31e-25	108
k141_126832_25	SARG|CAO78565	25.6	434	604	639	4.31e-25	108
k141_126832_25	SARG|WP_000691721.1	25.3	434	604	639	5.74e-25	108
k141_126832_25	SARG|ABC18245	25.3	434	604	639	5.74e-25	108
k141_126832_25	SARG|AAL30847	25.3	434	604	639	5.74e-25	108
k141_126832_25	SARG|DQ294299.gene.p01	25.3	434	604	639	5.74e-25	108
k141_126832_36	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	43.0	684	651	703	1.55e-170	502
k141_126832_68	CARD|gb|WKR28567.1|ARO:3007678|IreK	39.8	261	402	718	9.06e-58	199
k141_126832_70	SARG|CP001581.1.gene3143.p01	32.8	332	345	344	1.76e-51	173
k141_126832_70	SARG|gb|CAL84423.1|ARO:3004146|cfrC	32.5	332	345	344	1.35e-50	171
k141_126832_73	SARG|gi|507083067|ref|WP_016153816.1|	27.8	317	320	660	7.59e-27	109
k141_126832_73	SARG|gi|507086291|ref|WP_016157032.1|	27.4	317	320	660	2.55e-26	108
k141_126832_73	SARG|gi|851917461|ref|WP_048217311.1|	26.8	317	320	660	1.15e-25	106
k141_126832_73	SARG|gi|489117806|ref|WP_003027650.1|	26.8	317	320	660	1.15e-25	106
k141_126832_73	SARG|gi|765458296|ref|WP_044714032.1|	26.8	317	320	660	1.15e-25	106
k141_126832_73	SARG|gi|696375142|ref|WP_032949690.1|	26.8	317	320	660	1.15e-25	106
k141_126832_73	SARG|gi|851981245|ref|WP_048240645.1|	26.8	317	320	660	1.56e-25	105
k141_126832_73	SARG|gi|757799830|ref|WP_043017032.1|	26.8	317	320	660	2.85e-25	105
k141_126832_73	SARG|gi|851935911|ref|WP_048224705.1|	26.8	317	320	660	7.05e-25	103
k141_126832_73	SARG|gi|507079934|ref|WP_016150692.1|	26.5	317	320	660	9.52e-25	103
k141_126832_116	SARG|gb|WP_104671188.1|ARO:3003948|efrA	34.7	576	594	575	3.28e-100	315
k141_126832_116	SARG|gb|AAK76137.1|ARO:3000024|patA	37.0	541	594	564	3.02e-93	296
k141_126832_116	SARG|gi|496018010|ref|WP_008742581.1|	45.9	233	594	623	8.38e-59	206
k141_126832_116	SARG|gi|944470764|ref|WP_055701183.1|	45.2	239	594	601	1.09e-58	205
k141_126832_116	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	30.8	509	594	574	1.28e-58	204
k141_126832_116	SARG|gi|748767925|ref|WP_040019608.1|	45.8	240	594	623	1.60e-58	205
k141_126832_116	SARG|gi|926400371|ref|WP_053728483.1|	45.5	233	594	603	2.17e-58	204
k141_126832_116	SARG|gi|943909899|ref|WP_055545300.1|	44.8	239	594	601	5.55e-58	203
k141_126832_116	SARG|gb|AYV52072.1|ARO:3002882|lmrD	28.7	502	594	664	1.13e-57	204
k141_126832_116	SARG|gi|926351744|ref|WP_053683383.1|	45.9	233	594	648	2.31e-57	202
k141_126832_117	SARG|gb|AYV52072.1|ARO:3002882|lmrD	31.4	601	682	664	3.93e-89	291
k141_126832_117	SARG|gb|AAK76136.1|ARO:3000025|patB	32.2	568	682	588	7.47e-86	280
k141_126832_117	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	30.0	567	682	579	6.28e-73	245
k141_126832_117	SARG|gi|860594225|ref|WP_048475168.1|	31.0	549	682	620	1.54e-71	243
k141_126832_117	SARG|gi|1033217078|gb|OAR27197.1|	31.2	568	682	601	3.84e-71	241
k141_126832_117	SARG|gb|CDO61516.1|ARO:3003949|efrB	36.0	381	682	362	5.10e-71	234
k141_126832_117	SARG|gi|496018010|ref|WP_008742581.1|	30.6	549	682	623	1.63e-70	240
k141_126832_117	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	32.6	537	682	578	3.24e-70	238
k141_126832_117	SARG|gi|497748188|ref|WP_010062372.1|	31.0	545	682	605	8.04e-70	238
k141_126832_117	SARG|gi|948137056|ref|WP_056795395.1|	30.6	549	682	602	1.05e-69	237
